Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To support acceleration of research and development for AVI's exon skipping candidate drugs, for the treatment of DMD
Subscribe to our email newsletter
AVI and Action Duchenne have signed a collaboration agreement to support the acceleration of R&D for AVI’s exon skipping candidate drugs, for the treatment of DMD.
The agreement has a one-year term, with an option to extend for additional years. It is expected to provide approximately $1.2 million in support to AVI over the initial term for advancement of research, regulatory efforts and clinical trial recruitment.
Nick Catlin, CEO of Action Duchenne, said: AVI has a new class of candidate drugs which are an important contribution to Action Duchenne’s search for a treatment for DMD. We have teamed up with AVI to help accelerate these clinical programs as part of our commitment to cure this devastating disease.
Our primary goal is to help provide treatment options for the many children and adults afflicted with DMD. We believe we can provide significant value to AVI’s ground breaking efforts, he added.